Important Information for Investors of Actinium Pharmaceuticals, Inc.:
Rosen Law Firm, a leading global investor rights law firm, is reminding purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024 (the “Class Period”), of the significant May 26, 2025 lead plaintiff deadline. This deadline applies to those who may have claims against the Company and its officers and directors for alleged violations of the Federal Securities Laws.
What is the Class Action Lawsuit About?
The lawsuit alleges that Actinium Pharmaceuticals, Inc. and certain of its officers and directors made false and/or misleading statements and/or failed to disclose that: (1) the Company’s ACT-180 clinical trial results were not as strong as represented; (2) the Company’s ACT-180 clinical trial results would not support regulatory approval; and (3) as a result, Actinium’s public statements were materially false and misleading at all relevant times.
What Should I Do if I Purchased Actinium Securities During the Class Period?
If you purchased Actinium securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The lead plaintiff deadline is May 26, 2025. To get more information, you can contact the Rosen Law Firm’s Jared Rossman at 212-697-9691 or via email at [[email protected]](mailto:[email protected]).
How Will This Affect Me?
If you purchased Actinium securities during the Class Period and the allegations in the lawsuit are proven true, you could potentially recover your losses. The recovery process is typically simple and does not require any out-of-pocket costs or fees. The lead plaintiff will act on behalf of all investors in the class, and the compensation will be distributed among the class members.
How Will This Affect the World?
The outcome of this lawsuit could potentially have a ripple effect on the biotech industry, as it could lead to increased scrutiny of clinical trial results and regulatory approvals. This could impact investor confidence in the sector and potentially lead to changes in the way biotech companies report their clinical trial results and seek regulatory approvals.
- Increased scrutiny of clinical trial results and regulatory approvals
- Potential impact on investor confidence in the biotech industry
- Possible changes in the way biotech companies report clinical trial results and seek regulatory approvals
Conclusion:
If you purchased Actinium Pharmaceuticals securities between October 31, 2022, and August 2, 2024, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The lead plaintiff deadline is May 26, 2025. The outcome of this lawsuit could potentially have significant implications for the biotech industry and investor confidence. To get more information, contact the Rosen Law Firm’s Jared Rossman at 212-697-9691 or via email at [[email protected]](mailto:[email protected]).
